Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

480 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-31

Study Completion Date

2024-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to evaluate the immunogenicity and safety of DTaP or DT given in children aged 6 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children ( DTaP/DT )

NCT05870631

Vaccine Reaction

UNKNOWN PHASE4

A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed

NCT05091619

Whooping Cough Diphtheria Tetanus

ACTIVE_NOT_RECRUITING PHASE3

Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine

NCT00452686

Diphtheria Acellular Pertussis Tetanus

COMPLETED PHASE3

Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age

NCT00467519

Tetanus Diphtheria Pertussis

COMPLETED PHASE3

Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine

NCT06184542

Diphtheria Tetanus Pertussis

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A phase 4 trial was conducted in Zhejiang Province aimed to evaluate the immunogenicity and safety of DTaP or DT in children aged 6 years. DTaP and DT are produced by Wuhan Biological Products Co., LTD. Participants will be recruited and randomly divided into two groups to receive DTaP or DT in 1:1 ratio. Two blood samples were taken on Day 0 (pre-vaccination) and Day 28\~42 (after-vaccination) for test antibody against pertussis, diphtheria and tetanus. Adverse events and serious adverse events were actively collected by staff within 28 days of vaccination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaccine Reaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Group with DTap vaccination produced by Wuhan Institute of Biological Products Co., Ltd

Group Type EXPERIMENTAL

vaccinate with DTap

Intervention Type BIOLOGICAL

vaccinate with DTap

Group B

Group with DT vaccination

Group Type EXPERIMENTAL

vaccinate with DT

Intervention Type BIOLOGICAL

vaccinate with DT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vaccinate with DTap

Intervention Type BIOLOGICAL

vaccinate with DT

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants aged ≥ 6 on the day of enrollment;
2. Informed consent should be signed and dated by the participants;
3. The participant's legal guardian is able to attend all planned follow-up visits and comply with all study procedures;
4. The participants have received 4 doses of acellular TDap vaccine and have not received any immunization agents related to diphtheria, tetanus, and pertussis in the past 3 years;
5. The participant has no diease history of pertussis, diphtheria or tetanus;
6. ≥ 14 days interval between the last vaccination;
7. Body temperature was ≤37.3℃.

Exclusion Criteria

1. Being allergic to any component of vaccines ；
2. A history of severe allergic reactions to any vaccine (for example acute allergic reaction, angioneurotic edema, dyspnea, etc）；
3. Having a history or family history of convulsions, encephalopathy, psychosis, uncontrolled epilepsy and other progressive neurological diseases;
4. Participants are suffering from immunodeficiency, receiving immunosuppressant therapy (oral steroid hormones) during treatment for malignancy, or having low immunity due to HIV, or having congenital immune disorders in close family members;
5. Injection of non-specific immunoglobulin within 1 month before enrollment;
6. Participants are suffering from acute febrile diseases and infectious diseases;
7. A history of clearly diagnosed thrombocytopenia or other clotting disorders that may contraindicate subcutaneous injection;
8. Participants with severe chronic diseases or acute episodes of chronic diseases;
9. Participants with infectious, suppurative and allergic skin diseases;
10. Other Participants whose physical conditions, as determined by the investigator, are not suitable for inclusion in clinical studies.

Minimum Eligible Age

72 Months

Maximum Eligible Age

84 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes